Connect with us


Pneumonia vaccine may reduce impact of COVID-19: University of Melbourne study



Pneumonia vaccines can potentially reduce the impact of viruses such as Covid-19, said researchers, adding that it has reduced illness and death in patients with pneumonia, serious lung conditions and rotavirus, a common disease which causes severe diarrhoea and vomiting.
The University of Melbourne-led research team, which worked with the Fiji Ministry of Health and Medical Services, said the results underline the importance of vaccines and how they can potentially reduce the impact of viruses such as Covid-19.
Published in the journal ‘Lancet Regional Health – Western Pacific’, the first study looked at Fiji’s national rotavirus vaccine programme five years after it became the first independent Pacific island country to introduce the vaccine in 2012.

According to the researchers, rotavirus is severely contagious and the most common cause of diarrhoeal disease among infants and young children. It can even cause death in extreme cases.
After taking the vaccine, morbidity and mortality due to rotavirus and all-cause diarrhoea in Fiji fell in those aged two months to 55 years. Rotavirus diarrhoea admissions at the largest hospital among children aged under five fell by 87 per cent.
These reductions were most likely due to the vaccine as rotavirus diarrhoeal outbreaks remained blunted for the five years after vaccine introduction.

At the same time, in 2012, the Fiji government introduced a routine infant immunisation schedule for ten-valent pneumococcal conjugate (PCV10) vaccine using three primary doses and no booster dose.
Published in ‘The Lancet Global Health’, this second study looked at hospital admission rates for children with pneumonia at three Fiji public tertiary hospitals.
Five years after the vaccine was introduced, hospital admissions for all-cause pneumonia had fallen for children aged 24-59 months. Mortality was down by 39 per cent among children aged two to 24 months who were admitted to hospitals with all-case pneumonia, bronchiolitis and asthma.

The study showed the effect of PCV10 vaccine and supported its introduction for children in other low and middle-income countries in that region.
“These results provide supportive evidence of the probable benefits of PCV10 in reducing pneumonia in children in Fiji,” said study lead researcher Fiona Russell from the Murdoch Children’s Research Institute and the University of Melbourne.

Continue Reading


447 cases of adverse effect reported,Covid-19 vaccine given to 2,24,301 beneficiaries :Govt.



A total of 2,24,301 beneficiaries have been inoculated with COVID-19 vaccine so far, out of which only 447 adverse events following immunisation (AEFI) were reported, the Union Health Ministry said on day two of the nationwide vaccination drive on Sunday.

Addressing a press briefing, the ministry’s Additional Secretary Manohar Agnani said out of the 447 adverse events following immunisation, only three required hospitalisation.

“Today being Sunday, only six states conducted vaccination drive and in 553 sessions a total of 17,072 beneficiaries were vaccinated,” he said.

The six states where the vaccination drive was carried out on Sunday are Andhra Pradesh, Arunachal Pradesh, Karnataka, Kerala, Manipur and Tamil Nadu, he added.

Agnani said a total of 2,24,301 beneficiaries have been vaccinated till January 17 as per provisional reports, adding that 2,07,229 of them received the jabs on day one of the drive.

“A total of 447 AEFI have been reported on January 16 and 17, out of which only three required hospitalisation. Most of the AEFI reported so far are minor like fever, headache, nausea,” he said.

He said a meeting was held with all states and union territories on Sunday to review the progress of the drive, identify bottlenecks and plan corrective actions.

Prime Minister Narendra Modi rolled out the world’s largest inoculation drive against COVID-19 on Saturday and said the two vaccines being deployed will ensure a “decisive victory” for India against the pandemic.

India has approved two vaccines—Covaxin developed by Bharat Biotech and Covishield from the Oxford/AstraZeneca stable being manufactured by the Serum Institute of India—for emergency use in the country.

According to the government, the shots will be offered first to an estimated one crore healthcare workers and around two coror frontline workers, and then to persons above 50 years of age, followed by persons younger than 50 years of age with associated comorbidities. PTI

Continue Reading